Oryzon Genomics S.A. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 2.45 million compared to USD 2.36 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.04 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.952 EUR | -0.91% | -0.41% | +3.39% |
05-06 | Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-22 | Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.39% | 122M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- ORY Stock
- News Oryzon Genomics S.A.
- Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022